Ordensklinikum Linz - Elisabethinen

Kidney Transplantation After Rescue Allocation-the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. (2022) Assfalg V, Miller G, Stocker F, Van Meel M, Groenevelt T, Tieken I, Ankerst D, et al. Journal article Influence of gender on radiosensitivity during radiochemotherapy of advanced rectal cancer (2022) Schuster B, Hecht M, Schmidt M, Haderlein M, Jost T, Büttner-Herold M, Weber K, et al. Journal article Real-Life Cause-Effect Relations Between Urinary IL-6 Levels and Specific and Nonspecific Symptoms in a Patient With Mild SLE Disease Activity (2021) Schubert C, Seizer L, Chamson E, König P, Sepp N, Ocaña-Peinado FM, Schnapka-Köpf M, Fuchs D Journal article Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia (2021) Bazarbachi AH, Labopin M, Kroger N, Brecht A, Blaise D, Clausen J, Fanin R, et al. Journal article Continued versus interrupted targeted therapy during metastasis‐directed stereotactic radiotherapy: A retrospective multi‐center safety and efficacy analysis (2021) Kroeze SGC, Fritz C, Schaule J, Blanck O, Kahl KH, Kaul D, Siva S, et al. Journal article Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population (2020) Ludwig H, Poenisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, et al. Journal article Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma (2019) Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, et al. Journal article CLINICAL AND VIROLOGICAL CHARACTERISTICS AND RETREATMENT OF HCV-INFECTED PATIENTS WITH FAILURE TO MULTIPLE SUBSEQUENT DAA THERAPIES (2019) Dietz J, Vermehren J, Peiffer KH, Wietzke-Braun P, Muellhaupt B, Schattenberg J, Antoni C, et al. Conference contribution Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine (2019) Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, et al. Journal article Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD (2019) Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, et al. Journal article